Biodexa Pharmaceuticals (NASDAQ:BDRX) Posts Quarterly Earnings Results

Biodexa Pharmaceuticals (NASDAQ:BDRX) issued its earnings results on Friday. The company reported $0.70 earnings per share for the quarter, reports.

Biodexa Pharmaceuticals Price Performance

BDRX stock opened at $0.65 on Friday. The company’s 50-day moving average price is $1.25 and its 200 day moving average price is $3.91. Biodexa Pharmaceuticals has a 52 week low of $0.65 and a 52 week high of $19.30.

Biodexa Pharmaceuticals shares are set to reverse split before the market opens on Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, April 3rd.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC acquired a new position in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals comprises about 0.6% of Sabby Management LLC’s investment portfolio, making the stock its 10th biggest position. Sabby Management LLC owned 28.04% of Biodexa Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 17.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on BDRX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen raised Biodexa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.